Therapeutic intervention based on protein prenylation and associated modifications

In eukaryotic cells, a specific set of proteins are modified by C-terminal attachment of 15-carbon farnesyl groups or 20-carbon geranylgeranyl groups that function both as anchors for fixing proteins to membranes and as molecular handles for facilitating binding of these lipidated proteins to other proteins. Additional modification of these prenylated proteins includes C-terminal proteolysis and methylation, and attachment of a 16-carbon palmitoyl group; these modifications augment membrane anchoring and alter the dynamics of movement of proteins between different cellular membrane compartments. The enzymes in the protein prenylation pathway have been isolated and characterized. Blocking protein prenylation is proving to be therapeutically useful for the treatment of certain cancers, infection by protozoan parasites and the rare genetic disease Hutchinson-Gilford progeria syndrome.

[1]  H. Waldmann,et al.  Development and biological evaluation of acyl protein thioesterase 1 (APT1) inhibitors. , 2005, Angewandte Chemie.

[2]  J. Hancock,et al.  Ras signaling from plasma membrane and endomembrane microdomains. , 2005, Biochimica et biophysica acta.

[3]  M. Philips Methotrexate and Ras Methylation: A New Trick for an Old Drug? , 2004, Science's STKE.

[4]  Robert G Parton,et al.  H-ras, K-ras, and inner plasma membrane raft proteins operate in nanoclusters with differential dependence on the actin cytoskeleton , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  C. López-Otín,et al.  Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase–deficient mice , 2002, Nature Genetics.

[6]  R. Deschenes,et al.  Identification of a Ras Palmitoyltransferase in Saccharomyces cerevisiae * , 2002, The Journal of Biological Chemistry.

[7]  Karen N Conneely,et al.  Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Deschenes,et al.  DHHC9 and GCP16 Constitute a Human Protein Fatty Acyltransferase with Specificity for H- and N-Ras* , 2005, Journal of Biological Chemistry.

[9]  E. Gratton,et al.  Visualizing association of N-ras in lipid microdomains: influence of domain structure and interfacial adsorption. , 2006, Journal of the American Chemical Society.

[10]  A. Balmain,et al.  Absence of the CAAX Endoprotease Rce1: Effects on Cell Growth and Transformation , 2002, Molecular and Cellular Biology.

[11]  S. Michaelis,et al.  Endoplasmic reticulum membrane localization of Rce1p and Ste24p, yeast proteases involved in carboxyl-terminal CAAX protein processing and amino-terminal a-factor cleavage. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. W. Glynn,et al.  Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. , 2005, Human molecular genetics.

[13]  M. Teitell,et al.  Mutations in Costello Syndrome : Detection of Constitutional Activating Mutations in Codon 12 and 13 and Loss of Wild-Type Allele in Malignancy , 2005 .

[14]  M. Gelb,et al.  Thematic review series: Lipid Posttranslational Modifications. Fighting parasitic disease by blocking protein farnesylation Published, JLR Papers in Press, December 7, 2005. , 2006, Journal of Lipid Research.

[15]  J. Otto,et al.  Cloning and Characterization of a Mammalian Prenyl Protein-specific Protease* , 1999, The Journal of Biological Chemistry.

[16]  F. Tamanoi,et al.  Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways , 2005, Molecular Cancer Therapeutics.

[17]  M. Gelb,et al.  Palmitoylation of Ha-Ras Facilitates Membrane Binding, Activation of Downstream Effectors, and Meiotic Maturation in Xenopus Oocytes (*) , 1996, The Journal of Biological Chemistry.

[18]  R. Gibbs,et al.  The Isoprenoid Substrate Specificity of Isoprenylcysteine Carboxylmethyltransferase , 2005, Journal of Biological Chemistry.

[19]  S. Michaelis,et al.  Topological and mutational analysis of Saccharomyces cerevisiae Ste14p, founding member of the isoprenylcysteine carboxyl methyltransferase family. , 2001, Molecular biology of the cell.

[20]  J. Urano,et al.  Identification of novel single amino acid changes that result in hyperactivation of the unique GTPase, Rheb, in fission yeast , 2005, Molecular microbiology.

[21]  J. Otto,et al.  Targeted Inactivation of the Isoprenylcysteine Carboxyl Methyltransferase Gene Causes Mislocalization of K-Ras in Mammalian Cells* , 2000, The Journal of Biological Chemistry.

[22]  J. Rine,et al.  Modulation of Ras and a-Factor Function by Carboxyl-Terminal Proteolysis , 1997, Science.

[23]  S. Sebti,et al.  Design, synthesis, and evaluation of potent and selective benzoyleneurea-based inhibitors of protein geranylgeranyltransferase-I. , 2005, Bioorganic & medicinal chemistry.

[24]  R. Goody,et al.  Structure of doubly prenylated Ypt1:GDI complex and the mechanism of GDI‐mediated Rab recycling , 2006, The EMBO journal.

[25]  J. Yoo,et al.  H‐ras gene mutations in salivary gland mucoepidermoid carcinomas , 2000, Cancer.

[26]  Richard T Eastman,et al.  Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. , 2005, Current opinion in investigational drugs.

[27]  L. Beese,et al.  Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. , 2004, Biochemistry.

[28]  M. Gelb,et al.  Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Gelb,et al.  Substrate specificity of mammalian prenyl protein-specific endoprotease activity. , 1998, Biochemistry.

[30]  P. Casey,et al.  Targeting Ras signaling through inhibition of carboxyl methylation: An unexpected property of methotrexate , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Michaelis,et al.  A Novel Membrane-associated Metalloprotease, Ste24p, Is Required for the First Step of NH2-terminal Processing of the Yeast a-Factor Precursor , 1997, The Journal of cell biology.

[32]  J. Hancock,et al.  Ras proteins: different signals from different locations , 2003, Nature Reviews Molecular Cell Biology.

[33]  R. Baron,et al.  Thematic review series: Lipid Posttranslational Modifications. Geranylgeranylation of Rab GTPases Published, JLR Papers in Press, January 9, 2006. , 2006, Journal of Lipid Research.

[34]  L. Beese,et al.  Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes. , 2004, Biochemistry.

[35]  R. Leventis,et al.  Partitioning of lipidated peptide sequences into liquid-ordered lipid domains in model and biological membranes. , 2001, Biochemistry.

[36]  M. Gelb,et al.  Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[37]  T. Sasaki,et al.  Role of rab GDP dissociation inhibitor alpha in regulating plasticity of hippocampal neurotransmission. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  E. Henske,et al.  Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  P. Casey,et al.  Post-prenylation-processing enzymes as new targets in oncogenesis , 2005, Nature Reviews Cancer.

[40]  H. Waldmann,et al.  Synthesis and application of fluorescence-labeled Ras-proteins for live-cell imaging. , 2004, Angewandte Chemie.

[41]  Sangram S. Sisodia,et al.  Dual Roles for Ste24p in Yeast a-Factor Maturation: NH2-terminal Proteolysis and COOH-terminal CAAX Processing , 1998, The Journal of cell biology.

[42]  Joseph Avruch,et al.  Rheb Binds and Regulates the mTOR Kinase , 2005, Current Biology.

[43]  W. R. Bishop,et al.  The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling , 2005, Journal of Biological Chemistry.

[44]  A. Cox,et al.  PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. , 2006, Cancer research.

[45]  R. Baron,et al.  A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  T. Mak,et al.  RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. , 2005, Genes & development.

[47]  G. Benga From model membranes to isolated cells , 1989 .

[48]  C. Fierke,et al.  Upstream polybasic region in peptides enhances dual specificity for prenylation by both farnesyltransferase and geranylgeranyltransferase type I. , 2005, Biochemistry.

[49]  F. Tamanoi,et al.  Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells , 2001, Cellular and Molecular Life Sciences CMLS.

[50]  R. Deschenes,et al.  Erf2, a Novel Gene Product That Affects the Localization and Palmitoylation of Ras2 in Saccharomyces cerevisiae , 1999, Molecular and Cellular Biology.

[51]  J. Hancock,et al.  Individual Palmitoyl Residues Serve Distinct Roles in H-Ras Trafficking, Microlocalization, and Signaling , 2005, Molecular and Cellular Biology.

[52]  K. Kinzler,et al.  PRL-3 expression in metastatic cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  Protein prenyltransferases : Isoprenoids - Biosynthesis and role in the regulation of protein function , 1992 .

[54]  S. Pfeffer,et al.  Targeting Rab GTPases to distinct membrane compartments , 2004, Nature Reviews Molecular Cell Biology.

[55]  S. Carr,et al.  Structure of Saccharomyces cerevisiae mating hormone a-factor. Identification of S-farnesyl cysteine as a structural component. , 1988, The Journal of biological chemistry.

[56]  David K Williams,et al.  Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. , 2005, Journal of medicinal chemistry.

[57]  R. Tsien,et al.  Partitioning of Lipid-Modified Monomeric GFPs into Membrane Microdomains of Live Cells , 2002, Science.

[58]  J. Silvius Mechanisms of Ras Protein Targeting in Mammalian Cells , 2002, The Journal of Membrane Biology.

[59]  N. van Bruggen,et al.  Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[60]  M. Gelb,et al.  Exploring the specificity of prenyl protein-specific methyltransferase with synthetic prenylated rab peptides , 1995 .

[61]  C J Marshall,et al.  A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. , 1991, The EMBO journal.

[62]  M. Edidin The state of lipid rafts: from model membranes to cells. , 2003, Annual review of biophysics and biomolecular structure.

[63]  A. Gilman,et al.  A Cytoplasmic Acyl-Protein Thioesterase That Removes Palmitate from G Protein α Subunits and p21RAS * , 1998, The Journal of Biological Chemistry.

[64]  Yukichi Tanaka,et al.  Germline mutations in HRAS proto-oncogene cause Costello syndrome , 2005, Nature Genetics.

[65]  C. Dermardirossian,et al.  GDIs: central regulatory molecules in Rho GTPase activation. , 2005, Trends in cell biology.

[66]  J. Smotrys,et al.  Palmitoylation of intracellular signaling proteins: regulation and function. , 2004, Annual review of biochemistry.

[67]  M. Bergo,et al.  A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. , 2006, The Journal of clinical investigation.

[68]  Yuri K Peterson,et al.  A Novel Protein Geranylgeranyltransferase-I Inhibitor with High Potency, Selectivity, and Cellular Activity* , 2006, Journal of Biological Chemistry.

[69]  Gregory R. Hoffman,et al.  Structure of the Rho Family GTP-Binding Protein Cdc42 in Complex with the Multifunctional Regulator RhoGDI , 2000, Cell.

[70]  E. Zackai,et al.  HRAS mutation analysis in Costello syndrome: Genotype and phenotype correlation , 2006, American journal of medical genetics. Part A.

[71]  S. Michaelis,et al.  The Saccharomyces cerevisiae prenylcysteine carboxyl methyltransferase Ste14p is in the endoplasmic reticulum membrane. , 1998, Molecular biology of the cell.

[72]  D. Neal,et al.  Frequency of H-ras mutations in human bladder cancer detected by direct sequencing. , 1994, British journal of urology.

[73]  P. Rathod,et al.  Resistance to a Protein Farnesyltransferase Inhibitor in Plasmodium falciparum* , 2005, Journal of Biological Chemistry.

[74]  R. Rando,et al.  Inhibitors of the isoprenylated protein endoprotease. , 1993, Biochemistry.

[75]  Yosef Gruenbaum,et al.  Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson–Gilford progeria syndrome , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[76]  W. R. Bishop,et al.  Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors Published, JLR Papers in Press, November 8, 2005. , 2006, Journal of Lipid Research.

[77]  Sebastian Maurer-Stroh,et al.  Protein prenyltransferases , 2003, Genome Biology.

[78]  J. Silvius Lipidated peptides as tools for understanding the membrane interactions of lipid-modified proteins , 2002 .

[79]  P. Casey,et al.  Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. , 2004, The Journal of clinical investigation.

[80]  J. Lippincott-Schwartz,et al.  Depalmitoylated Ras traffics to and from the Golgi complex via a nonvesicular pathway , 2005, The Journal of cell biology.

[81]  E. Dolence,et al.  Studies with recombinant Saccharomyces cerevisiae CaaX prenyl protease Rce1p. , 2000, Biochemistry.

[82]  S. Michaelis,et al.  The Multispanning Membrane Protein Ste24p Catalyzes CAAX Proteolysis and NH2-terminal Processing of the Yeast a-Factor Precursor* , 2001, The Journal of Biological Chemistry.

[83]  J. Karp,et al.  Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. , 2001, Blood.

[84]  Laura Scott,et al.  Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome , 2003, Nature.

[85]  M. Gelb,et al.  Rab geranylgeranyl transferase catalyzes the geranylgeranylation of adjacent cysteines in the small GTPases Rab1A, Rab3A, and Rab5A. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[86]  G. Ahmann,et al.  Farnesyltransferase inhibitor FTI‐R115777 is well tolerat ed, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma , 2003, Blood.

[87]  J. Hancock,et al.  Three Separable Domains Regulate GTP-Dependent Association of H-ras with the Plasma Membrane , 2004, Molecular and Cellular Biology.

[88]  S. Sakakibara,et al.  Chemical synthesis of proteins. , 1995, Biopolymers.

[89]  J. Otto,et al.  Disruption of the Mouse Rce1 Gene Results in Defective Ras Processing and Mislocalization of Ras within Cells* , 1999, The Journal of Biological Chemistry.

[90]  S. Young,et al.  Thematic Review Series: Lipid Posttranslational Modifications. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria—new evidence suggesting that protein farnesylation could be important for disease pathogenesis Published, JLR Papers in Press, October 5, 2005. DOI 10.1194/jlr.R500011-JLR200 , 2005, Journal of Lipid Research.

[91]  J. Rine,et al.  The CaaX Proteases, Afc1p and Rce1p, Have Overlapping but Distinct Substrate Specificities , 2000, Molecular and Cellular Biology.

[92]  Petra Ross-Macdonald,et al.  Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. , 2005, Cancer cell.

[93]  W. R. Bishop,et al.  Lipid posttranslational modifications. Farnesyl transferase inhibitors. , 2006, Journal of lipid research.

[94]  M. Resh,et al.  Inhibition of Protein Palmitoylation, Raft Localization, and T Cell Signaling by 2-Bromopalmitate and Polyunsaturated Fatty Acids* , 2000, The Journal of Biological Chemistry.

[95]  J. Couchman,et al.  RhoGDI: multiple functions in the regulation of Rho family GTPase activities. , 2005, The Biochemical journal.

[96]  C. Fuchs,et al.  Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. , 2002, Molecular cancer therapeutics.

[97]  W. K. Schmidt,et al.  Mutational Analysis of the Ras Converting Enzyme Reveals a Requirement for Glutamate and Histidine Residues* , 2006, Journal of Biological Chemistry.

[98]  R. Rando,et al.  Substrate specificity of the isoprenylated protein endoprotease. , 1992, Biochemistry.

[99]  J Deisenhofer,et al.  Crystal structure of Rab geranylgeranyltransferase at 2.0 A resolution. , 2000, Structure.

[100]  A. Pampel,et al.  Structural model of the membrane-bound C terminus of lipid-modified human N-ras protein. , 2006, Angewandte Chemie.

[101]  Katherine A Brown,et al.  Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. , 2003, Molecular and biochemical parasitology.

[102]  M. Shipitsin,et al.  Activation of RalA is critical for Ras-induced tumorigenesis of human cells. , 2005, Cancer cell.

[103]  Stephen B. Long,et al.  Reaction path of protein farnesyltransferase at atomic resolution , 2002, Nature.

[104]  W. R. Bishop,et al.  K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors* , 1997, The Journal of Biological Chemistry.

[105]  L. Dietrich,et al.  On the mechanism of protein palmitoylation , 2004, EMBO reports.

[106]  M. Gelb,et al.  Cloning, Heterologous Expression, and Distinct Substrate Specificity of Protein Farnesyltransferase from Trypanosoma brucei * , 2000, The Journal of Biological Chemistry.

[107]  Y. Sakagami,et al.  Isolation of a Novel Sex Hormone, Tremerogen A-10, Controlling Conjugation Tube Formation in Tremella mesenterica Fries , 1978 .

[108]  M. Gelb,et al.  Prenyl proteins in eukaryotic cells: a new type of membrane anchor. , 1990, Trends in biochemical sciences.

[109]  M. Gelb,et al.  A Designed Probe for Acidic Phospholipids Reveals the Unique Enriched Anionic Character of the Cytosolic Face of the Mammalian Plasma Membrane* , 2004, Journal of Biological Chemistry.

[110]  M. Bergo,et al.  Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases. , 2005, Molecular biology of the cell.

[111]  M. Gelb,et al.  Identification of geranylgeranyl-modified proteins in HeLa cells. , 1990, Science.

[112]  P. Casey,et al.  Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. , 2004, Journal of molecular biology.

[113]  A. Wittinghofer,et al.  Ras-A Molecular Switch Involved in Tumor Formation. , 2000, Angewandte Chemie.

[114]  M. Gelb,et al.  A protein geranylgeranyltransferase from bovine brain: implications for protein prenylation specificity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[115]  M. Gelb,et al.  Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[116]  Herbert Waldmann,et al.  An Acylation Cycle Regulates Localization and Activity of Palmitoylated Ras Isoforms , 2005, Science.

[117]  J. Otto,et al.  Isoprenylcysteine Carboxyl Methyltransferase Deficiency in Mice* , 2001, The Journal of Biological Chemistry.

[118]  R. Deschenes,et al.  New insights into the mechanisms of protein palmitoylation. , 2003, Biochemistry.

[119]  R. Rando,et al.  Solubilization, partial purification, and affinity labeling of the membrane-bound isoprenylated protein endoprotease. , 1996, Biochemistry.

[120]  Y. Kamiya,et al.  Requirements of chemical structure of hormonal activity of lipopeptidyl factors inducing sexual differentiation in vegetative cells of heterobasidiomycetous yeasts. , 1978, Biochemical and biophysical research communications.

[121]  K. Burgess,et al.  A labeled guanidine ligand for studying sweet taste. , 1998, Bioorganic & Medicinal Chemistry Letters.

[122]  S. Michaelis,et al.  Nucleotide sequence of the yeast STE14 gene, which encodes farnesylcysteine carboxyl methyltransferase, and demonstration of its essential role in a-factor export , 1994, Molecular and cellular biology.

[123]  Eric S. Lander,et al.  Genomic analysis of metastasis reveals an essential role for RhoC , 2000, Nature.

[124]  Herbert Waldmann,et al.  Bioorganic synthesis of lipid-modified proteins for the study of signal transduction , 2000, Nature.

[125]  D. Lawrence,et al.  Structure-activity studies of cerulenin analogues as protein palmitoylation inhibitors. , 1999, Journal of medicinal chemistry.

[126]  M. Philips,et al.  Thematic review series: Lipid Posttranslational Modifications CAAX modification and membrane targeting of Ras Published, JLR Papers in Press, March 16, 2006. , 2006, Journal of Lipid Research.

[127]  J. Hancock,et al.  Ras plasma membrane signalling platforms. , 2005, The Biochemical journal.

[128]  P. Casey,et al.  Structure of mammalian protein geranylgeranyltransferase type‐I , 2003, The EMBO journal.

[129]  J. Goldstein,et al.  Polylysine and CVIM Sequences of K-RasB Dictate Specificity of Prenylation and Confer Resistance to Benzodiazepine Peptidomimetic in Vitro(*) , 1995, The Journal of Biological Chemistry.

[130]  Edward S. Kim,et al.  Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors , 2004, Clinical Cancer Research.

[131]  L. Aravind Type II CAAX prenyl endopeptidases belong to a novel superfamily of putative membrane-bound metalloproteases , 2001 .

[132]  S. Michaelis,et al.  Purification, Functional Reconstitution, and Characterization of the Saccharomyces cerevisiae Isoprenylcysteine Carboxylmethyltransferase Ste14p*♦ , 2005, Journal of Biological Chemistry.

[133]  M. Gelb,et al.  Human lamin B contains a farnesylated cysteine residue. , 1989, The Journal of biological chemistry.

[134]  P. Casey,et al.  Non-peptidic, non-prenylic inhibitors of the prenyl protein-specific protease Rce1. , 2001, Bioorganic & medicinal chemistry letters.

[135]  J. Otto,et al.  On the Physiological Importance of Endoproteolysis of CAAX Proteins , 2004, Journal of Biological Chemistry.

[136]  M. Smith,et al.  The Tuberous Sclerosis complex , 1993 .

[137]  P. Casey,et al.  The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 A resolution ternary complex structures. , 2000, Structure.

[138]  Stephen G Young,et al.  A Protein Farnesyltransferase Inhibitor Ameliorates Disease in a Mouse Model of Progeria , 2006, Science.

[139]  S. Hahn,et al.  Farnesyltransferase inhibitors. , 2001, Seminars in oncology.